AlphaFold 3
AI system that predicts the structure and interactions of all of life's molecules
Model · OtherCompany source
Company profile
About B Isomorphic
Isomorphic Labs is pioneering a new era of drug discovery by applying frontier artificial intelligence to unlock deeper scientific insights and accelerate the development of life-changing medicines. Founded by Sir Demis Hassabis, the company builds upon and extends beyond the Nobel Prize-winning AlphaFold system to advance human health through digital biology. The company's interdisciplinary team brings together drug discovery experts and machine learning specialists who have developed powerful predictive and generative AI models that operate at digital speed. Their foundational Drug Design Engine is capable of generating drug candidates against challenging targets across multiple modalities including small molecules, antibodies, peptides, and molecular glues. Isomorphic Labs has established strategic research collaborations with leading pharmaceutical companies including Novartis, Eli Lilly and Company, and Johnson & Johnson. These partnerships combine Iso's AI-first approach with partners' extensive drug discovery expertise to identify novel molecules and address diseases that have historically been out of reach. The company's mission reflects the belief that there is an underlying symmetry between biology and information science—an isomorphism that AI can harness to model complex biological phenomena and develop innovative medicines to treat and cure some of the world's most devastating diseases.
Company description B Isomorphic official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Work at B Isomorphic?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Biotech companies
- Contract Research Organizations (CROs)
- Pharmaceutical companies
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsSwitzerland · United States
Company sourceOfficial website
Company milestones
Platform expansion
Series B investment round announced February 2025; Drug Design Engine unveiled February 2025; Johnson & Johnson collaboration announced January 2026; Novartis collaboration expanded February 2025 (adding up to three additional research programs); $600M external investment round March 2025; Dr. Ben Wolf appointed Chief Medical Officer and US presence established June 2025; Max Jaderberg appointed President November 2025
Partnerships
Recorded partners
- Eli Lilly and Company
- Google DeepMind
- Johnson & Johnson
- Novartis
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Isomorphic Labs Drug Design Engine
AI-powered multi-modality drug discovery platform built on AlphaFold technology
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Exploration of new chemical spaces unavailable through traditional methods
As stated by Novartis President of Biomedical Research regarding partnership progress
Johnson & Johnson
Multi-target, cross-modality research collaboration developing therapeutics across small molecules and biologics for challenging diseases
Novartis
Discovery of small molecule therapeutics against challenging targets using AI-powered drug design
Exploration of new chemical spaces unavailable through traditional methods; partnership expanded from 3 to 6 research programs within one year
Eli Lilly and Company
Strategic research collaboration for discovering small molecule therapeutics against undisclosed targets
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from B Isomorphic
Recent articles published on B Isomorphic's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.